Pfizer Canada is investing $500,000 in McMaster projects to address critical gaps in health equity during vaccine development and delivery. This investment, announced at McMaster University on Apr. 23, 2024, aims to support the university’s commitment to inclusive excellence in research. Specifically, it will train emerging scholars from equity-deserving groups in vaccinology and support students conducting vaccine research focused on vulnerable populations susceptible to infectious diseases.
Despite the effectiveness of vaccines, systemic disparities in representation, efficacy, distribution, and uptake persist. In response, Pfizer is backing McMaster’s efforts to promote inclusive excellence in vaccine development and delivery.